NEW YORK (GenomeWeb) – Finnish MDx firm Mobidiag said today that it has expanded its distribution agreement with PerkinElmer subsidiary Wallac to include distribution of its Amplidiag product line in Israel and several countries in Africa.
Mobidiag’s Amplidiag line includes in vitro diagnostic tests for the detection of gastrointestinal infections, including Clostridium difficile and bacterial gastroenteritis, and well as drug-resistant organisms, supported by cartridge-based multiplex PCR and microarray instruments.
Wallac has been distributing Amplidiag products in South Africa since January. Mobidiag CEO Tuomas Tenkanen said in a statement that the companies are now extending that deal to both speed up sales coverage in Africa — expanding to Botswana, Ghana, Ivory Coast, Kenya, Mauritius, Morocco, Mozambique, Nigeria, Rwanda, Senegal, and Uganda — and also to extend availability of the system into the Middle East.
“We are very pleased that PerkinElmer will continue to support us in our endeavor with its acknowledged expertise and worldwide leadership in the field of diagnostics,” Tenakanen added.
Financial and other terms of the deal were not disclosed.
In Europe, Mobidiag has also steadily added distributors over the last year, covering Italy, Sweden and Norway, Portugal, and the UK, among others.